Sirtris Pharmaceuticals of Cambridge,
USA announced yesterday strong positive results from an
early-stage clinical trial targeting type 2 diabetes for
a drug based on resveratrol, the chemical found in red wine,
reports Boston Herald.
The study, done on 98 diabetes patients
in India who had never been treated for the disease, was
aimed at determining the safety of two different doses of
the drug known as SRT501. In addition to finding that the
drug was well-tolerated in the 28-day trial, CEO Christoph
Westphal said the company "saw a strong trend toward
SRT501 lowering glucose."
"It was an unexpected surprise,"
said Westphal. "We believe this is the first time a
drug candidate targeted to the genes that control the aging
process has been shown to be beneficial in human patients
in a disease of aging."
Past study results have led some to dub
SRT501 as a "fountain of youth" drug because of
its potential to target a range of diseases of aging.
Phase 2 of the study will be a three-month
programme and will include 130 patients and yield results
later this year. Still, despite positive early results,
SRT501 is at least four years away from market, says Westphal.